Ontario denies US cancer drug for stage-4 patients, sparking criticism over cost policy

Ontario’s health system has turned down out-of-country funding for a U.S.-approved personalized T-cell therapy, leaving stage-4 cancer patients such as 31-year-old Sabrina Apitz-Grossman without access. Despite her doctors’ recommendation, the Ontario Health Insurance Plan denied the request, and an appeal under the Case-by-Case Review Program failed. Health Minister Sylvia Jones announced a rule change that now only funds overseas drugs already covered in the province, claiming it will protect taxpayers and avoid up to $5.2 billion in extra costs.

The move follows a court victory by Alex Shved, which the government says merely clarifies existing policy. Critics, including patients and advocates, contend the restriction blocks potentially life-saving treatments that manufacturers have no plans to seek Canadian approval for. The therapy, Tecelra, costs US$727,000 and offers a 90 % one-year survival chance for responders. The controversy highlights tensions between cost containment and access to experimental cancer care.